Objective: To identify the causative gene of autosomal dominant paroxysmal kinesigenic dyskinesia and benign familial infantile seizures (PKD/BFIS) in a large Chinese family and explore the potential pathogenic mechanism of a PRRT2 (proline-rich transmembrane protein 2) variant. Methods: Genetic testing was performed via whole exome sequencing. Western 
| INTRODUCTION
Paroxysmal kinesigenic dyskinesia (PKD) and benign familial infantile seizure (BFIS) are related autosomal dominant neurological disorders and can occur either alone or in combination. 1 PKD is the most common form of paroxysmal movement disorder, characterized by recurrent, brief attacks of abnormal involuntary movements triggered by sudden voluntary movements with onset in late childhood or early adulthood. 2 Neurological examinations of PKD patients are generally normal, and there is no loss of consciousness or pain during attacks. BFIS usually occurs in infancy, with onset between 4 and 12 months of age, and is characterized by brief seizures with cyanosis, hypertonia, motor arrest, and limb jerks. 1 The symptoms of PKD and BFIS can be alleviated in most patients with antiepileptic drugs. 2, 3 Mutations in PRRT2, 4 ,5 KCNA1, 6 SCN8A, 7 and POC1B 8 have been associated with PKD or PKD/BFIS, among which PRRT2 is the major causative gene of PKD, BFIS, and combined PKD and BFIS (known as infantile convulsions and choreoathetosis). 9 More than 90 mutations in PRRT2 have been identified thus far, 10 and seizure phenotypes such as febrile seizures and epilepsy have also been reported in PRRT2 mutation carriers. 9, [11] [12] [13] [14] The PRRT2 protein consists of a large proline-rich domain located in the cytoplasm, a helix-loop-helix (HLH) domain embedded in the inner surface of the plasma membrane, and a transmembrane domain that spans the plasma membrane. 15 PRRT2 is a key component of the calciumdependent neurotransmitter release machinery. 16 A recent study indicated that PRRT2 could interact with members of the SNARE complex, SNAP25 and STX1A, to regulate the SNARE complex formation. 17 However, no mutation in STX1A has been demonstrated to be associated with human disease. Interestingly, STX1B, but not STX1A, is necessary for the regulation of synaptic vesicle exocytosis 18 and brain development. 19 Zebrafish in which Stx1b is knocked down show seizurelike behavior, 20 and homozygous Stx1b-knockout mice display severe ataxia. 21 More important, STX1B
has been reported to be linked to febrile seizures and epilepsy. 20 Although both PRRT2 and STX1B participate in presynaptic vesicle exocytosis, and mutations of these genes could cause partially overlapping phenotypes, it is unclear whether there is a direct functional connection between PRRT2 and STX1B.
In this study, we recruited and characterized a four-generation family with autosomal dominant PKD/BFIS and identified a c.621dupA variant (p.Ser208Ilefs*17) in PRRT2 via whole exome sequencing. Moreover, we found that PRRT2 directly interacts with STX1B through its HLH domain. The truncated PRRT2 p.Ser208Ilefs*17 protein is expressed at a significantly reduced level, and the variant abrogates the interaction with STX1B, which may play a causative role in the pathogenesis of the PKD/BFIS cases investigated in this study.
| MATERIALS AND METHODS

| Families and patients
A Chinese Han family with autosomal dominant PKD/ BFIS was identified in Hubei Province. All of the participants in this study signed written informed consent forms before all experiments. Their clinical information was initially obtained from Union Hospital of Huazhong University of Science and Technology, and a detailed clinical examination was performed at Xiangya Hospital of Central South University. For genetic testing, DNA was extracted from peripheral blood samples obtained from the family members using standard methods, as previously reported. 22 
| Exome sequencing and screening of candidate genes
Exome sequencing of the proband (III:14) of the PKD/ BFIS family was carried out. In total, 17 809 nonsynonymous variants, splice-site variations, and coding indels were found in the sequenced exome. We then compared the protein-disrupting variants with the dbSNP135, 1000 Genomes, and HapMap databases, and an Asian genome to exclude polymorphisms. After the filtering step, 1731 candidates remained. We then screened for detrimental variants using Mutation Master, PolyPhen-2, and SIFT. 
Key Points
| Mutation analysis
Mutation analysis was conducted via polymerase chain reaction (PCR)-based Sanger sequencing. We sequenced candidate genes in four patients (III-14, II-3, II-6, and IV-3) to determine whether they all carried the same variant. Once the variant was identified, further cosegregation analysis in the entire family was performed.
| Restriction fragment length polymorphism analysis
Restriction fragment length polymorphism analysis was used to determine whether the variant cosegregated with the disease in the family and was absent in 200 normal controls. Considering that there was no appropriate restriction enzyme site near the variant, we used created restriction site PCR to detect the variant in this family.
Created restriction site PCR is a method that creates a restriction enzyme site by introducing mismatched nucleotides into the 3′ end of a PCR primer adjacent to the variant. The PRRT2 gene was amplified using the following PCR primers: 5′-tcactcaccaccctcaaaagga-3′ (forward primer) and 5′-tcggggagatcctggatgc-3′ (reverse primer). The 121-bp PCR product was digested with BamH1 (New England Biolabs, Ipswich, MA, USA) at 37°C for 12 hours and then separated in a 4.0% agarose gel.
| Cell culture and treatment
HeLa cells and Neuro-2A (N2A) cells were routinely cultured in antibiotic-free Dulbecco modified Eagle medium (Gibco, Grand Island, NY, USA) with 10% fetal bovine serum (Gibco). The cells were transfected with a plasmid vector using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).
| Plasmid construction
The full-length STX1B and PRRT2 cDNA sequences were amplified via real-time PCR from a cDNA library generated using SH-SY5Y cells. We then cloned the full-length STX1B cDNA sequence into the pEGFP-C1 and pET-28a expression vectors and cloned the fulllength PRRT2 cDNA sequence into the p3×FLAG (DYKDDDDK tag)-MYC-CMV-24 and pGEX-6p-1 vectors. Plasmids carrying PRRT2-S208Ifs*17, three missense mutants (PRRT2 S275F, W281R, and A287T), and truncated PRRT2 were generated based on the PRRT2-wild-type (WT) plasmid and verified by sequencing. The primers used for the truncated plasmids and mutagenesis plasmids are summarized in Table S1 . For the endogenous co-IP experiment, protein was extracted from N2A cells using 2 mL of cell lysis buffer for Western blot and IP analyses. The supernatant was then collected via centrifugation at 12 000 g for 10 minutes. Thereafter, the supernatant was incubated overnight with a rabbit anti-STX1B antibody (ab188583; Abcam, Cambridge, MA, USA), and subsequent steps were performed as described above. Finally, immunoblotting was performed with an anti-Stx1b antibody or anti-Prrt2 antibody (ab211307, Abcam).
| Protein purification and glutathione
S-transferase pull-down assay
Protein purification was performed as previously described. 23 In brief, the recombinant plasmids pGEX-glutathione S-transferase (GST)-PRRT2 and pET-28a-STX1B were transformed into Escherichia coli Rosetta cells, and expression was induced by isopropyl thiogalactoside at 16°C for 20 hours. The cells were then harvested, lysed using ultrasound, and centrifuged to separate the supernatant. The soluble cell lysates containing GST-PRRT2 were incubated with GST beads at 4°C for 4 hours and then washed with phosphate-buffered saline (PBS) buffer. Additionally, the expression products of His-STX1B were incubated with nickel affinity resin (Ni-NTA; Qiagen, Valencia, CA, USA) at 4°C for 4 hours, and the GST-PRRT2 protein was then eluted from the affinity resin with wash buffer plus 300 mmol/L imidazole. For the GST pulldown assay, the eluted His protein was collected and incubated with GST beads, followed by washing as described above for 2 hours at 4°C. Finally, after washing the GST beads again three times, sodium dodecyl sulfate-polyacrylamide gel electrophoresis was used to detect the binding of PRRT2 and STX1B.
| Immunofluorescence
N2A cells were transfected with appropriate plasmids and then fixed in 10% methanol for 15 minutes, rinsed with PBS, permeabilized with PBS containing 0.5% Triton X-100, and blocked with 5% Albumin Bovine V. Thereafter, they were incubated with primary antibodies (anti-FLAG: 1:1000, M185-3L, MBL International) overnight at 4°C and then washed three times with PBS, followed by incubation with secondary antibodies (1454439; Life Technologies, Carlsbad, CA, USA). Finally, nuclei were stained with 4,6-diamidino-2-phenylindole. All images were captured using an FV1000 confocal microscope (Olympus, Tokyo, Japan). Colocalization was evaluated via immunofluorescence using standard methods.
| Cell fractionation
Cell fractionation was performed as previously reported. 24 Briefly, N2A cells were transfected with FLAG-PRRT2 and GFP-STX1B, harvested after 24 hours, and lysed with 1.0 mL of ice-cold cell fractionation buffer (40 mmol/L Hepes, 150 mmol/L NaCl, 1 mmol/L ethylenediaminetetraacetic acid, 5 mmol/L ethyleneglycoltetraacetic acid, complete protease inhibitor cocktail). Following sonication, 100 μL of the total lysate was retained as a control (total protein) for Western blotting. Cell debris and nuclei were removed from the remaining lysate via low-speed centrifugation at 400 g for 10 minutes at 4°C, followed by separation into cytosol and membrane fractions via ultracentrifugation at 100 000 g for 60 minutes at 4°C. The membrane pellets were gently washed twice in cell fractionation buffer. Proteins obtained through cell fractionation were denatured by boiling in loading buffer. The samples were then subjected to Western blotting with GFP and FLAG antibodies, followed by ImageJ (National Institutes of Health, Bethesda, MD, USA) densitometric analysis to quantify the FLAG-PRRT2 and GFP-STX1B proteins in each fraction.
| RESULTS
| Clinical features
A total of 21 family members were involved in the study, showing a wide spectrum of clinical heterogeneity ( Figure 1A ). The proband (III-14) was a 31-year-old man who has suffered from PKD since he was 12 years old.
The clinical manifestations of his PKD phenotype include involuntary twisting of the torso and limb spasms, which are usually triggered by sudden movement, changes in velocity, being startled, or fatigue. These attacks mainly occur in the unilateral lower limbs and can spread from one side to the other, lasting for a few seconds and generally not for >30 seconds. Unconsciousness is not observed during these attacks. A frequency of 10-20 times per day was noted. The proband experiences a premonition before the attack, and slowing down can reduce the number of attacks. He began to exhibit partial epilepsy after falling from a height and suffering head trauma at the age of 17 years, which subsequently developed into generalized tonic-clonic seizures (GTCS), involving foaming at the mouth, upward rolling of the eyes, and loss of consciousness. The proband's interictal electroencephalographic data were normal ( Figure S1 ), whereas brain magnetic resonance imaging showed a small focus of softening in the right temporal lobe caused by trauma ( Figure S2 ), which may be associated with the epileptic seizures. In addition, family member III:1 has a history of birth asphyxia and hypoxia and exhibited slightly lower intelligence than her peers at developmental milestones. She shows symptoms of GTCS, which may have been elicited by a divorce at the age of 26 years. The other patients in this pedigree exhibit either PKD/BFIS or BFIS alone. The clinical features of this family are summarized in Table 1 .
| Mutation analysis
Because the phenotypes of this family were initially diagnosed as febrile seizures and partial epilepsy, we first performed direct Sanger sequencing of STX1B in the proband, but no pathogenic variants were found. To identify the pathogenic gene responsible for the disease in this family, whole exome sequencing of the proband (III:14) was conducted. Based on the exome sequencing data, a variant Western blot analysis (Figure 2B and 2C; n = 4, P < .001). WT-PRRT2 primarily localized to the cell membrane, whereas the truncated mutant was located mainly in the cytoplasm and showed a significantly weak fluorescence intensity (Figure 2D and 2E ; n ≥ 100 cells from three independent experiments, P < .001).
| The HLH domain of PRRT2 interacts with STX1B
Considering that mutations in PRRT2 and STX1B cause partially overlapping seizure phenotypes 11, 20 and that PRRT2
and STX1B can bind to SNAP25, 5, 25 we sought to explore whether PRRT2 interacts with STX1B. Reciprocal co-IP assays showed that the immobilized fusion protein GFP-STX1B could bind to FLAG-PRRT2 ( Figure 3A and 3B) . As the human PRRT2 and STX1B proteins are highly homologous to mouse prrt2 and stx1b ( Figure S3 ), we further analyzed whether there is an interaction between endogenous prrt2 and stx1b. Consistent with the exogenous results, stx1b coimmunoprecipitated with prrt2 ( Figure 3C ). Furthermore, a purified STX1B-HIS protein could be pulled down by GST-PRRT2 ( Figure 3D ). These findings suggest a direct interaction between PRRT2 and STX1B, which may play important roles in a protein complex with SNAP25 in the physiological activities of neurons in the brain.
To identify which domain of PRRT2 plays a key role in the interaction with STX1B, we constructed four plasmids expressing various truncated proteins (FLAG-PRRT2-▵293-315, FLAG-PRRT2-▵293-340, FLAG-PRRT2-▵269-289, and FLAG-PRRT2-▵1-266; Figure 3E ). The three mutants containing the HLH domain could interact with STX1B, but the mutant in which the HLH domain was deleted (FLAG-PRRT2-▵269-289) could not interact with STX1B ( Figure 3F ). Furthermore, we demonstrated that the p.Ser208Ilefs*17 mutant could not bind to STX1B due to loss of the HLH domain ( Figure 4A ). WT-PRRT2 and STX1B colocalized at the cell membrane of N2A cells, but the truncated mutant p.Ser208Ilefs*17 did not colocalize with STX1B ( Figure 4B ).
Based on these results, we propose that the HLH domain plays a critical role in the interaction between PRRT2 and , and red represents the 17 amino acids affected by the frameshift variant. B, Analysis of the expression levels of WT-PRRT2 and the truncated p.Ser208Ilefs*17 PRRT2 protein in HeLa cells. The~65-kDa band represents FLAG-tagged WT-PRRT2, and the band smaller than 65 kDa represents the FLAG-tagged truncated p.Ser208Ilefs*17 mutant. Actin was used as an internal reference protein. C, Quantification of FLAG-PRRT2/β-actin in the Western blot, which was normalized to the value obtained for FLAG-PRRT2-WT. The data are presented as mean ± SEM. ***P < .001) using the two-tailed t test. D, The localization of WT-PRRT2 and the truncated p.Ser208Ilefs*17 mutant in Neuro-2A (N2A) cells. Representative images show that the FLAG-tagged WT-PRRT2 is located at the cell membrane (red), and the truncated p.Ser208Ilefs*17 mutant is mainly located in the cytoplasm (red). E, The fluorescence values of WT-PRRT2 and p.Ser208Ilefs*17 mutant in ≥100 transfected N2A cells in each group were quantified by ImageJ. Data are mean ± SEM from three independent experiments; statistical significance (***P < .001) was evaluated using unpaired t test. DAPI, 4,6-diamidino-2-phenylindole STX1B. In addition, multiple sequence alignments of PRRT2 proteins indicated that the HLH domain that interacts with the inner surface of the plasma membrane is highly conserved evolutionarily ( Figure S4 ) and may therefore play an important role in the physiological function of PRRT2.
| Missense variants in the HLH domain of PRRT2 increase cytoplasmic localization and interaction with STX1B
To further explore the role of the HLH domain in carrying out the physiological function of PRRT2, we selected three missense variants (S275F, W281R, and A287T) found in PKD/BFIS patients that are located in the HLH domain 26 and studied their colocalization and interaction with STX1B. Plasmids encoding either WT or mutant FLAG-PRRT2 and the GFP-STX1B fusion protein were cotransfected into N2A cells for immunofluorescence assays. Consistent with the localization of the PRRT2 A287T mutant, which has been reported to be mainly cytoplasmic, 27 both S275F and W281R showed an abnormal cytoplasmic distribution (Figure 5A) . To quantify the abundance of these proteins in the cytosol and membrane, respectively, we carried out subcellular fractionation of N2A cells coexpressing GFP-STX1B and FLAG-PRRT2. We found that the three mutant proteins did not significantly differ from WT in terms of their total levels ( Figure 5B and 5C), but these proteins did show significantly increased levels in the cytosol and reduced localization to the membrane (Figure 5B and 5C; n = 3, P < .001). In addition, GFP-STX1B was mainly distributed in the cytoplasm, and its localization was not affected by these PRRT2 mutants ( Figure 5B and 5D) . Furthermore, we found that the three PRRT2 mutants displayed increased interactions with STX1B (Figure 5E and 5F; n = 6). Consistent with the co-IP data, the three mutated PRRT2 proteins showed strong colocalization with STX1B in the cytoplasm, which was not observed in cells expressing the WT protein ( Figure 5A ).
| DISCUSSION
The relationship between epilepsies and other paroxysmal disorders such as PKD has been known for quite some time, , and orange represents the C-terminal extracellular domain. F, Mapping of the HLH domain of PRRT2 that interacts with STX1B. Co-IP assays showed that truncation mutants lacking the HLH domain (FLAG-PRRT2-▵269-289) did not interact with STX1B, whereas the other three mutants that retained the HLH domain were able to interact with STX1B. Input was whole cell extracts. *IgG-heavy chain band because these disorders involve involuntary movements and can be triggered by various types of stimuli. Based on the GTCS experienced by the proband (III:14) and Patient III:1, the phenotype of this family was initially diagnosed as epilepsy. After the identification of the PRRT2 variant in this family, the clinical phenotype was re-evaluated and finally confirmed as PKD/BFIS. Magnetic resonance imaging also suggested that the GTCS experienced by the proband (III:14) was secondary epilepsy caused by brain injury, rather than by the PRRT2 variant. As the disease was correctly diagnosed, some patients have begun treatment with carbamazepine, the most frequently reported anticonvulsant, rather than using other antiepileptic drugs such as valproate or traditional Chinese medicine. After a period of treatment, the symptoms of PKD were relieved. Therefore, genetic testing can help neurologists make fast and accurate judgments regarding various paroxysmal disorders and can help patients receive timely treatment with proper medicine.
More than 90 PRRT2 mutations have been identified to date. 10 Moreover, many mutations leading to a premature stop codon produce an unstable mRNA/protein that is rapidly degraded. 28 Consistent with previous findings, 28, 29 we found that the truncated p.Ser208Ilefs*17-PRRT2 20 which are also reported in patients carrying PRRT2 mutations. 11 As mentioned above, PRRT2 and STX1B can interact with SNAP25. 5, 25 In this study, PRRT2 was found to bind STX1B through its HLH domain ( Figure 3F ). Considering our results together with previous findings, 16 we speculate that the interaction between STX1B and PRRT2 may contribute to the function of the SNARE complex in maintaining synaptic vesicle exocytosis, and the inability of the truncated p.Ser208Ilefs*17-PRRT2 mutant to bind STX1B due to loss of the HLH domain might have a serious effect on neurotransmitter release. Missense variants in the HLH domain of PRRT2 lead to its abnormal localization in the cytoplasm, rather than the cell membrane ( Figure 5A ), suggesting a potential role of the HLH domain in mediating the subcellular localization of PRRT2. It is plausible that similar to the truncated p.Ser208Ilefs*17 mutant, the three variants in the HLH domain may impact synaptic exocytosis by reducing the distribution of PRRT2 to the plasma membrane, where PRRT2 exerts its normal physiological function via interaction with STX1B. Furthermore, we observed increased interactions between these PRRT2 missense mutants and STX1B ( Figure 5E and 5F), which may result from increased colocalization of the PRRT2 mutant with STX1B in the cytoplasm ( Figure 5A-C) . However, the precise regulatory mechanism underlying the interaction between PRRT2 and STX1B remains unclear. Recently, PRRT2 has been reported to regulate the assembly of the SNARE complex, synaptic vesicle docking, and fusion. 34, 36 Considering that cerebellar synaptic dysfunction due to PRRT2 deficiency is closely related to the occurrence of PKD, 37 it would be interesting to determine whether and how PRRT2 modulates the formation of SNARE complexes containing STX1B in the cerebellum. In summary, we identified a truncated mutant of PRRT2, p.Ser208Ilefs*17, which lacks the HLH domain and thus fails to interact with STX1B. The mutant protein shows decreased expression and abnormal subcellular localization, leading to synaptic dysfunction and excitatory-inhibitory neurotransmitter imbalance, which may be the pathogenic mechanism of PKD/BFIS in the family examined in this study.
